Global Gorlin Syndrome Market - Industry Trends and Forecast to 2028

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Gorlin Syndrome Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Sep 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Gorlin Syndrome Market, By Therapy Type (Topical Chemotherapy, Photodynamic Therapy), Treatment Type (Medication, Surgery), Drugs (Itraconazole, Vismodegib, Others), Route of Administration (Oral, Topical and Others), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Gorlin Syndrome Market Market Analysis and Insights : Global Gorlin Syndrome Market

Gorlin syndrome market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 4.70% in the above mentioned forecast period.

Gorlin syndrome is a rare genetic disorder which affects the skin, brain, bones and other organs. The signs and symptoms of this condition include rib malformation, broad face and an extraordinary predisposition to basal cell carcinoma. It occurs due the changes in the PTCH1 gene. This is a tumor suppressor gene and defect in these genes will results in the Gorlin syndrome in people. Gorlin syndrome is also called nevoid basal cell carcinoma syndrome.

Rise in the prevalence of Gorlin syndrome, financial support to the researches involved in the development of novel intervention and growing demand of disease specific novel treatment are the factors that will expand the Gorlin syndrome market. The competitive scenario of market and strategic collaborations also boost the market growth.

High unmet need and emerging new markets will provide beneficial opportunities for the Gorlin syndrome market in the forecast period of 2021-2028.

However, high cost of treatment and diagnosis coupled with the unfavourable reimbursement scenario are the factors that will hinder the market growth. Less operating revenue opportunities for research and development of targeted therapies by various pharmaceuticals will challenge the Gorlin syndrome market in the forecast period mentioned above.

This Gorlin syndrome market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Gorlin syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Gorlin Syndrome Market Scope and Market Size

  • The Gorlin syndrome market is segmented on the basis of therapy type, treatment type, drugs, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
  • On the basis of therapy type, the Gorlin syndrome market is segmented into topical chemotherapy and photodynamic therapy.
  • On the basis of treatment type, the Gorlin syndrome market is segmented into medication and surgery.
  • On the basis of drugs, the Gorlin syndrome market is segmented into itraconazole, vismodegib and others.
  • On the basis of route of administration, the Gorlin syndrome market is segmented into oral, topical and others.
  • On the basis of end-users, the Gorlin syndrome market is segmented into hospitals, homecare, specialty clinics and others.
  • The Gorlin syndrome market is also segmented on the basis of distribution channel into hospital pharmacies, retail pharmacies and others.

Gorlin Syndrome Market Country Level Analysis

Gorlin syndrome market is analyzed and market size information is provided by the country, therapy type, treatment type, drugs, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Gorlin syndrome market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the Gorlin syndrome market due to the presence of major key players, high disposable income, high healthcare expenditure and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, surge in the investment for healthcare sector and increase in the disposable income.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Gorlin syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Gorlin Syndrome Market Share Analysis

Gorlin syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Gorlin syndrome market research.

The major players covered in the Gorlin syndrome market report are LEO Pharma A/S, Mayne Pharma Group Limited, PellePharm, Inc, Novartis AG, Mylan N.V., Jubilant Pharmova Limited, Amneal Pharmaceuticals LLC, Alkem Labs, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Johnson & Johnson Private Limited, among other domestic and global players.  Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL GORLIN SYNDROME MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL GORLIN SYNDROME MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY BASED MODEL

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL GORLIN SYNDROME MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S 5 FORCES

6 EPIDEMIOLOGY

7 INDUSTRY INSIGHTS

8 REGULATORY FRAMEWORK

9 PIPELINE ANALYSIS

9.1 OVERVIEW

9.2 PHASE III CANDIDATES

9.3 PHASE II CANDIDATES

9.4 PHASE I CANDIDATES

9.5 OTHERS

10 IMPACT OF COVID-19 PANDEMIC ON THE MARKET

10.1 PRICE IMPACT

10.2 IMPACT ON DEMAND

10.3 IMPACT ON SUPPLY CHAIN

10.4 STRATEGIC DECISIONS FOR MANUFACTURERS

10.5 CONCLUSION

11 GLOBAL PRION DISEASE TREATMENT MARKET, BY TREATMENT

11.1 OVERVIEW

11.2 MEDICATION

11.2.1 PHOTODYNAMIC THERAPY/ HEDGEHOG PATHWAY INHIBITORS

11.2.1.1. SONIDEGIB

11.2.1.2. VISMODEGIB

11.2.1.3. PATIDEGIB HYDROCHLORIDE

11.2.1.4. ITRACONAZOLE

11.2.1.5. OTHERS

11.2.2 TOPICAL CHEMOTHERAPY

11.2.2.1. FLUOROURACIL

11.2.2.2. IMIQUIMOD

11.2.2.3. OTHERS

11.3 SURGERY

11.3.1 MOHS MICROGRAPHIC SURGERY (MMS)

11.3.2 CRYOSURGERY

11.3.3 ELECTRODESSICATION AND CURETTAGE

11.3.4 LASER VAPORIZATION

11.3.5 OTHERS

11.4 RADIATION THERAPY

11.5 OTHERS

12 GLOBAL GORLIN SYNDROME MARKET, BY GENE TYPE

12.1 PTCH1

12.2 PTCH2

12.3 SUFU

13 GLOBAL GORLIN SYNDROME MARKET, BY DIAGNOSIS

13.1 IMAGING

13.1.1 MRI

13.1.2 ULTRASOUND

13.1.3 X-RAY

13.2 MOLECULAR GENETIC TESTING

13.3 OTHERS

14 GLOBAL GORLIN SYNDROME MARKET, BY AGE GROUP

14.1 OVERVIEW

14.2 PADEATRICS

14.3 ADULTS

14.4 GERIATRICS

15 GLOBAL GORLIN SYNDROME MARKET, BY ROUTE OF ADMINISTRATION

15.1 OVERVIEW

15.2 ORAL

15.3 INJECTABLES

15.4 OTHERS

16 GLOBAL GORLIN SYNDROME MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.3 HOMECARE

16.4 SPECIALTY CLINICS

16.5 OTHERS.

17 GLOBAL GORLIN SYNDROME MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 DIRECT TENDER

17.3 RETAIL SALES

17.4 ONLINE RETAIL CHANNELS

17.5 OTHERS

18 GLOBAL GORLIN SYNDROME MARKET, BY GEOGRAPHY

18.1 GLOBAL GORLIN SYNDROME MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

18.1.1 NORTH AMERICA

18.1.1.1. U.S.

18.1.1.2. CANADA

18.1.1.3. MEXICO

18.1.2 EUROPE

18.1.2.1. GERMANY

18.1.2.2. FRANCE

18.1.2.3. U.K.

18.1.2.4. HUNGARY

18.1.2.5. LITHUANIA

18.1.2.6. AUSTRIA

18.1.2.7. IRELAND

18.1.2.8. NORWAY

18.1.2.9. POLAND

18.1.2.10. ITALY

18.1.2.11. SPAIN

18.1.2.12. RUSSIA

18.1.2.13. TURKEY

18.1.2.14. BELGIUM

18.1.2.15. NETHERLANDS

18.1.2.16. SWITZERLAND

18.1.2.17. REST OF EUROPE

18.1.3 ASIA-PACIFIC

18.1.3.1. JAPAN

18.1.3.2. CHINA

18.1.3.3. SOUTH KOREA

18.1.3.4. INDIA

18.1.3.5. AUSTRALIA

18.1.3.6. SINGAPORE

18.1.3.7. THAILAND

18.1.3.8. MALAYSIA

18.1.3.9. INDONESIA

18.1.3.10. PHILIPPINES

18.1.3.11. VIETNAM

18.1.3.12. REST OF ASIA-PACIFIC

18.1.4 SOUTH AMERICA

18.1.4.1. BRAZIL

18.1.4.2. ARGENTINA

18.1.4.3. PERU

18.1.4.4. REST OF SOUTH AMERICA

18.1.5 MIDDLE EAST AND AFRICA

18.1.5.1. SOUTH AFRICA

18.1.5.2. SAUDI ARABIA

18.1.5.3. UAE

18.1.5.4. EGYPT

18.1.5.5. KUWAIT

18.1.5.6. ISRAEL

18.1.5.7. REST OF MIDDLE EAST AND AFRICA

19 GLOBAL GORLIN SYNDROME MARKET, COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: GLOBAL

19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

19.3 COMPANY SHARE ANALYSIS: EUROPE

19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19.5 MERGERS & ACQUISITIONS

19.6 NEW PRODUCT DEVELOPMENT & APPROVALS

19.7 EXPANSIONS

19.8 REGULATORY CHANGES

19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

20 GLOBAL GORLIN SYNDROME MARKET, SWOT AND DBMR ANALYSIS

21 GLOBAL GORLIN SYNDROME MARKET, COMPANY PROFILE

21.1 TEVA PHARMACEUTICAL INDUSTRIES LTD

21.1.1 COMPANY OVERVIEW

21.1.2 REVENUE ANALYSIS

21.1.3 GEOGRAPHIC PRESENCE

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENTS

21.2 TARO PHARMACEUTICAL INDUSTRIES LTD.

21.2.1 COMPANY OVERVIEW

21.2.2 REVENUE ANALYSIS

21.2.3 GEOGRAPHIC PRESENCE

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 MAYNE PHARMA GROUP LIMITED

21.3.1 COMPANY OVERVIEW

21.3.2 REVENUE ANALYSIS

21.3.3 GEOGRAPHIC PRESENCE

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENTS

21.4 ACCORD-UK LTD.

21.4.1 COMPANY OVERVIEW

21.4.2 REVENUE ANALYSIS

21.4.3 GEOGRAPHIC PRESENCE

21.4.4 PRODUCT PORTFOLIO

21.4.5 RECENT DEVELOPMENTS

21.5 HILL DERMACEUTICALS, INC

21.5.1 COMPANY OVERVIEW

21.5.2 REVENUE ANALYSIS

21.5.3 GEOGRAPHIC PRESENCE

21.5.4 PRODUCT PORTFOLIO

21.5.5 RECENT DEVELOPMENTS

21.6 PELLEPHARM

21.6.1 COMPANY OVERVIEW

21.6.2 REVENUE ANALYSIS

21.6.3 GEOGRAPHIC PRESENCE

21.6.4 PRODUCT PORTFOLIO

21.6.5 RECENT DEVELOPMENTS

21.7 KINTARA THERAPEUTICS, INC.

21.7.1 COMPANY OVERVIEW

21.7.2 REVENUE ANALYSIS

21.7.3 GEOGRAPHIC PRESENCE

21.7.4 PRODUCT PORTFOLIO

21.7.5 RECENT DEVELOPMENTS

21.8 GLENMARK GENERICS INC

21.8.1 COMPANY OVERVIEW

21.8.2 REVENUE ANALYSIS

21.8.3 GEOGRAPHIC PRESENCE

21.8.4 PRODUCT PORTFOLIO

21.8.5 RECENT DEVELOPMENTS

21.9 SUN PHARMACEUTICAL INDUSTRIES, INC

21.9.1 COMPANY OVERVIEW

21.9.2 REVENUE ANALYSIS

21.9.3 GEOGRAPHIC PRESENCE

21.9.4 PRODUCT PORTFOLIO

21.9.5 RECENT DEVELOPMENTS

21.1 GENENTECH, INC

21.10.1 COMPANY OVERVIEW

21.10.2 REVENUE ANALYSIS

21.10.3 GEOGRAPHIC PRESENCE

21.10.4 PRODUCT PORTFOLIO

21.10.5 RECENT DEVELOPMENTS

21.11 MYLAN N.V.

21.11.1 COMPANY OVERVIEW

21.11.2 REVENUE ANALYSIS

21.11.3 GEOGRAPHIC PRESENCE

21.11.4 PRODUCT PORTFOLIO

21.11.5 RECENT DEVELOPMENTS

21.12 PAR PHARMACEUTICAL.

21.12.1 COMPANY OVERVIEW

21.12.2 REVENUE ANALYSIS

21.12.3 GEOGRAPHIC PRESENCE

21.12.4 PRODUCT PORTFOLIO

21.12.5 RECENT DEVELOPMENTS

21.13 JANSSEN PHARMACEUTICALS, INC.

21.13.1 COMPANY OVERVIEW

21.13.2 REVENUE ANALYSIS

21.13.3 GEOGRAPHIC PRESENCE

21.13.4 PRODUCT PORTFOLIO

21.13.5 RECENT DEVELOPMENTS

21.14 MACLEODS PHARMACEUTICALS LTD.

21.14.1 COMPANY OVERVIEW

21.14.2 REVENUE ANALYSIS

21.14.3 GEOGRAPHIC PRESENCE

21.14.4 PRODUCT PORTFOLIO

21.14.5 RECENT DEVELOPMENTS

21.15 PERRIGO COMPANY PLC

21.15.1 COMPANY OVERVIEW

21.15.2 REVENUE ANALYSIS

21.15.3 GEOGRAPHIC PRESENCE

21.15.4 PRODUCT PORTFOLIO

21.15.5 RECENT DEVELOPMENTS

21.16 3M

21.16.1 COMPANY OVERVIEW

21.16.2 REVENUE ANALYSIS

21.16.3 GEOGRAPHIC PRESENCE

21.16.4 PRODUCT PORTFOLIO

21.16.5 RECENT DEVELOPMENTS

21.17 TAIHO PHARMACEUTICAL CO., LTD

21.17.1 COMPANY OVERVIEW

21.17.2 REVENUE ANALYSIS

21.17.3 GEOGRAPHIC PRESENCE

21.17.4 PRODUCT PORTFOLIO

21.17.5 RECENT DEVELOPMENTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

22 RELATED REPORTS

23 CONCLUSION

24 QUESTIONNAIRE

25 ABOUT DATA BRIDGE MARKET RESEARCH

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Industry Related Reports

Testimonial